Skip to main content
. 2022 Nov 24;55:101746. doi: 10.1016/j.eclinm.2022.101746

Fig. 4.

Fig. 4

Recurrence-free survival comparison between neoadjuvant therapy vs no neoadjuvant therapy in the propensity score matched group (n = 625), missing data on recurrences (n = 83). Hazard ratio 1.04 (95% CI: 0.87–1.25), p-value 0.66. Median OS 12.3 months in the neoadjuvant group (95% CI: 10.9–13.6) vs 12.6 months in the no neoadjuvant group (95% CI: 11.2–14.1), log rank p-value 0.66.